HIBADH

HIBADH encodes an NAD+-dependent 3-hydroxyisobutyrate dehydrogenase that oxidizes 3-hydroxyisobutyrate within the valine catabolic pathway, an activity established by heterologous reconstitution of the human enzyme (PMID:16466957) and confirmed in patient cells where loss-of-function alleles abolish activity and cause urinary accumulation of L-3-hydroxyisobutyric acid (PMID:34176136, PMID:35174513). Biallelic HIBADH mutations cause a primary 3-hydroxyisobutyric aciduria; notably, HIBADH is genetically distinct from ALDH6A1-driven forms of the same metabolite phenotype, in which HIBADH activity is normal (PMID:34176136, PMID:35174513, PMID:21863277). Structural and mechanistic work on bacterial orthologs defines the enzyme as a dimer that binds NAD+ and substrate in an interdomain cleft, preferentially acting on the S-enantiomer of hydroxyisobutyrate, with a conserved active-site cysteine (Cys-210 in the M. tuberculosis ortholog) required to position the substrate-entry loop for catalysis (PMID:29959185, PMID:33724683, PMID:27120461). Beyond core catabolism, HIBADH localizes to the mitochondria-derived sperm mid-piece where its activity tracks with motility (PMID:23423614), and gain-of-function studies in renal tubular cells show it limits mitochondrial oxidative stress and apoptosis, protecting against calcium oxalate crystal injury (PMID:40334962). The neurological consequences of HIBADH deficiency are attributable to the accumulating substrate 3-hydroxyisobutyric acid, which drives nitrosative stress and respiratory-chain impairment in developing brain (PMID:41422170).

1. 2006 High

   Established that the human HIBADH gene product is itself a functional 3-hydroxyisobutyrate dehydrogenase, fixing the enzymatic identity of the encoded protein.

   Evidence Heterologous expression of human HIBADH cDNA in E. coli with enzymatic activity assay

   PMID:16466957

   Open questions at the time

   • Did not address physiological substrate stereochemistry
   • No structure or active-site mapping
   • No in vivo or disease link
2. 2011 Medium

   Distinguished HIBADH from ALDH6A1 as a cause of 3-hydroxyisobutyric aciduria, showing that not all cases of the metabolite phenotype reflect HIBADH defects.

   Evidence Enzymatic activity assay and Sanger sequencing of HIBADH and ALDH6A1 in patient fibroblasts

   PMID:21863277

   Open questions at the time

   • Negative result for HIBADH; did not yet demonstrate any HIBADH-causative case
   • Did not resolve the full genetic heterogeneity of the phenotype
3. 2013 Medium

   Linked HIBADH to a tissue-specific role by placing it in the mitochondria-derived sperm mid-piece with activity correlating to motility, suggesting a function beyond hepatic valine catabolism.

   Evidence Immunofluorescence, western blot, and enzymatic activity assays in human sperm fractions stratified by motility

   PMID:23423614

   Open questions at the time

   • Correlative, not causal, link between activity and motility
   • Mechanism connecting catabolic activity to motility unresolved
4. 2013 Low

   Reported a candidate physical partner (14-3-3σ) for HIBADH from an interaction screen, raising the possibility of regulatory binding.

   Evidence Yeast two-hybrid screen of HeLa cDNA with co-immunoprecipitation in HEK293FT cells

   PMID:23840115

   Open questions at the time

   • Single Co-IP confirmation of a Y2H hit without reciprocal validation
   • No functional consequence of the interaction tested
   • Biological relevance to HIBADH catalysis unknown
5. 2015 Medium

   Provided functional genetic evidence that HIBADH expression level influences sperm motility, via a promoter SNP that reduces transcription.

   Evidence Truncated promoter-luciferase reporter assays, bisulfite sequencing, and SNP genotyping in 307 bulls

   PMID:26133183

   Open questions at the time

   • Association in bovine population; human relevance not tested
   • Mechanistic basis of motility dependence on HIBADH activity unresolved
6. 2018 High

   Defined the catalytic architecture of the enzyme — dimeric assembly, NAD+ and substrate binding in the interdomain cleft, substrate entry route, and S-HIBA preference — using bacterial orthologs.

   Evidence X-ray crystallography of multiple ligand complexes of M. tuberculosis HIBADH plus gel filtration, native PAGE, mutagenesis, and activity assays; complemented by B. cereus structures (PMID:27120461) and T. thermophilus crystallization (PMID:14646099)

   PMID:14646099 PMID:27120461 PMID:29959185

   Open questions at the time

   • Structural work on bacterial orthologs, not the human enzyme
   • Oligomeric state varies across orthologs (dimer vs tetramer)
7. 2021 High

   Pinpointed a single active-site cysteine (Cys-210) as critical for catalysis by maintaining the conformation of the substrate-entry loop, refining the catalytic mechanism.

   Evidence Site-directed mutagenesis, thiol chemical modification, kinetics, and structural analysis of M. tuberculosis HIBADH

   PMID:33724683

   Open questions at the time

   • Defined in the bacterial ortholog; conservation/role in human enzyme not directly tested
   • Catalytic chemistry of hydride transfer not fully dissected
8. 2021 High

   Proved HIBADH causality in human disease by tying a loss-of-function allele to abolished enzyme activity and urinary 3HiB accumulation, establishing HIBADH-deficient 3-hydroxyisobutyric aciduria.

   Evidence Patient mutation analysis (NMD), fibroblast enzyme activity, urinary metabolite quantification, dietary intervention; expanded by an additional patient cohort

   PMID:34176136 PMID:35174513

   Open questions at the time

   • Genotype-phenotype correlations across variants incomplete
   • Mechanism linking metabolite accumulation to neurological manifestations not addressed here
9. 2025 Medium

   Demonstrated a cytoprotective function for HIBADH in renal tubular cells, where it limits mitochondrial oxidative stress and apoptosis during crystal injury.

   Evidence Overexpression and siRNA knockdown in HK-2 cells, AAV2/9 gene transfer in a rat CaOx nephrolithiasis model, and Mito-TEMPO pharmacological rescue

   PMID:40334962

   Open questions at the time

   • Whether protection requires catalytic activity vs a moonlighting role is unclear
   • Single lab; mechanism upstream of mitochondrial ROS undefined
10. 2025 Medium

    Identified nitrosative stress as the downstream mediator of substrate (3HIBA) neurotoxicity, explaining the neurological phenotype of HIBADH deficiency at the level of the accumulating metabolite.

    Evidence In vitro and intracerebroventricular 3HIBA administration in rats with respiratory-chain and antioxidant assays and L-NAME rescue

    PMID:41422170

    Open questions at the time

    • Effects studied for the metabolite, not HIBADH protein directly
    • Relevance to chronic human disease course not established

• The structure and catalytic determinants of the human enzyme, and whether HIBADH's renal cytoprotective and sperm functions depend on its dehydrogenase activity, remain unresolved.
• No structural model of the human protein
• Catalytic vs non-catalytic basis of cytoprotection untested
• Functional consequence of 14-3-3σ binding unknown